<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201461</url>
  </required_header>
  <id_info>
    <org_study_id>G980031</org_study_id>
    <secondary_id>CLOSURE I</secondary_id>
    <nct_id>NCT00201461</nct_id>
  </id_info>
  <brief_title>Evaluation of the STARFlex速 Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex速 Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NMT Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NMT Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine whether the STARFlex速 septal closure&#xD;
      system will safely and effectively prevent a recurrent embolic stroke/transient ischemic&#xD;
      attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the&#xD;
      STARFlex速 device compared to best medical therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2003</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two (2) year incidence of stroke or Hard TIA</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality for the first 30 days of follow up/discharge, whichever is longer</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological mortality from 31 days of follow up (F/U) or longer</measure>
    <time_frame>31 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary endpoint as a total and broken down by event type/treatment group in: stroke/TIA patients (pts) and DW-MR+ pts with symptoms &lt; 24 hours</measure>
    <time_frame>&lt; 24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary endpoint in BMT group</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per treatment group, incidence of relevant/notable adverse events (AEs)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device group: (1) Incidence of primary endpoint in pts prescribed aspirin (325 versus 81 mg) daily, (2) Incidence of relevant/notable AEs</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <condition>Stroke</condition>
  <condition>Ischemic Attack, Transient</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STARFlex arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STARFlex septal closure system</intervention_name>
    <description>transcatheter placement of STARFlex device to close a patent foramen ovale</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best medical therapy</intervention_name>
    <description>aspirin (325 mg daily) and/or warfarin (target INR = 2.5)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years inclusive.&#xD;
&#xD;
          -  Positive contrast valsalva bubble study by trans-esophageal echocardiogram (TEE) for&#xD;
             patent foramen ovale (PFO), with or without atrial septal aneurysm.&#xD;
&#xD;
          -  Stroke or clinically definite TIA (contact study coordinator).&#xD;
&#xD;
          -  Be able to comply with follow up over two years.&#xD;
&#xD;
          -  Be competent to, or have a legal guardian competent to, provide informed consent&#xD;
             following full disclosure of risks and benefits of both treatment arms by a study&#xD;
             investigator.&#xD;
&#xD;
          -  Venous access capable of accepting a 10F minimum vascular sheath.&#xD;
&#xD;
          -  Have, or be willing to, discontinue hormonal based contraceptive use prior to&#xD;
             enrollment and for the term of the study.&#xD;
&#xD;
          -  Has cardiac anatomy based on enrollment echocardiogram that will allow for placement&#xD;
             of the implant if randomized to the implant arm.&#xD;
&#xD;
          -  Note: Additional inclusion criteria may apply. Contact study coordinator or principal&#xD;
             investigator for details.&#xD;
&#xD;
        Post-randomization - device patients only&#xD;
&#xD;
          -  The size of the PFO (measured by indentation with a soft balloon) must be amenable to&#xD;
             selection of a STARFlex device.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  Carotid artery stenosis &gt; 50%.&#xD;
&#xD;
          -  Intracranial stenosis &gt; 50% appropriate to symptoms.&#xD;
&#xD;
          -  Complex aortic arch atheroma with high risk features for embolism&#xD;
&#xD;
          -  Aortic arch, carotid or vertebral artery dissection.&#xD;
&#xD;
          -  Mitral or aortic valve stenosis, vegetation, or calcification &gt; 5 mm mitral annular&#xD;
             calcification (MAC) thickness.&#xD;
&#xD;
          -  Active pregnancy.&#xD;
&#xD;
          -  Active infections (contact study coordinator).&#xD;
&#xD;
          -  Active infective endocarditis or bacteremia.&#xD;
&#xD;
          -  Prosthetic heart valves in any location.&#xD;
&#xD;
          -  Anterior MI within 3 months of neurological event.&#xD;
&#xD;
          -  Chronic atrial fibrillation&#xD;
&#xD;
          -  Thrombus in, or occluded, venous access route.&#xD;
&#xD;
          -  Contraindication to heparin, aspirin, clopidogrel, or warfarin, or a known medical&#xD;
             condition that requires continuous warfarin.&#xD;
&#xD;
          -  Patient enrolled in another investigation study where clinical endpoint interference&#xD;
             may occur.&#xD;
&#xD;
          -  Permanent pacemaker or inferior vena cava (IVC) filter.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Patients with known vasculitis or neurologic disorder.&#xD;
&#xD;
          -  Baseline modified Rankin score of 3 or more.&#xD;
&#xD;
          -  Hypercoagulopathies requiring long-term warfarin.&#xD;
&#xD;
          -  Note: Additional exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Furlan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Foundation, Cleveland, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Reisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center, Seattle, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>STARFlex</keyword>
  <keyword>CLOSURE I</keyword>
  <keyword>Septal Closure System</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular Accident</keyword>
  <keyword>Transient Ischemic Attack</keyword>
  <keyword>Heart Septal Defects, Atrial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

